Isoxazolo[5,4-H]quinazoline CDK Inhibitor Patent
Summary
USPTO granted patent US12600731B2 to Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. for isoxazolo[5,4-H]quinazoline compounds effective as cyclin-dependent kinase (CDK) inhibitors for treating cell proliferation disorders. The patent contains 23 claims and covers pharmaceutical compositions and methods of treating CDK-mediated diseases.
What changed
USPTO granted patent US12600731B2 to Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. for a class of isoxazolo[5,4-H]quinazoline compounds effective as broad-spectrum cyclin-dependent kinase (CDK) inhibitors. The patent covers pharmaceutical compositions comprising these compounds and methods of treating CDK-mediated diseases including cell proliferation disorders.
For pharmaceutical and biotechnology companies engaged in CDK inhibitor research and development, this patent grant establishes enforceable intellectual property rights that may affect freedom-to-operate analyses, R&D investment decisions, and competitive positioning in the oncology and cell proliferation disorder therapeutic space.
What to do next
- Monitor for updates on related patent applications
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Isoxazolo[5,4-H]quinazoline compounds as protein kinase inhibitors
Grant US12600731B2 Kind: B2 Apr 14, 2026
Assignee
Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd.
Inventors
Hang Cheng, Weiyan Xiong, Bin Yu, Wei Niu
Abstract
The present disclosure provides a class of isoxazolo[5,4-H]quinazoline compounds represented by general formula (I), which can be used to treat cell proliferation disorders, and are effective cyclin-dependent kinase (CDK) inhibitors, which have a broad-spectrum and strong inhibitory activity against CDK. The present disclosure also provides a pharmaceutical composition comprising the compound, and a method of treating and/or preventing a CDK-mediated disease in a subject, including administering the compound or the composition of the present disclosure.
CPC Classifications
A61P 35/00 C07D 498/04
Filing Date
2020-09-03
Application No.
17640115
Claims
23
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.